Six IPOs and five SPACs priced this week. Two IPOs and eight SPACs submitted filings. Cardiovascular disease biotech Braveheart Bio (BRVE) upsized and priced above the range, raising $383 million at a $1.6 billion market cap. Its lead candidate, BHB-1893, is ...read more
Braveheart Bio, a Phase 3-ready biotech developing oral small molecules for cardiovascular diseases, raised $383 million by offering 21.3 million shares at $18, above the $15 to $17 range. It had originally planned to offer 18.8 million shares. Fidelity had...read more
Updated Monday, 8/3. Six IPOs are currently scheduled for the week ahead, featuring five biotechs and a California bank. Mega-issuer SpaceX (SPCX) will also be in focus as it reports earnings for the first time as a public company ahead of a partial lock-up...read more
IPO Winners & Losers: New Stocks Surge, Biotech Booms, and AI Rallies
Welcome back to Renaissance Capital’s IPO Winners and Losers, the weekly podcast breaking down the biggest stories shaping the IPO market. Click here to get the newsletter in your inbox every week.
...read moreUS IPO Weekly Recap: August kicks off with flurry of biotech IPOs
Six IPOs and five SPACs priced this week. Two IPOs and eight SPACs submitted filings. Cardiovascular disease biotech Braveheart Bio (BRVE) upsized and priced above the range, raising $383 million at a $1.6 billion market cap. Its lead candidate, BHB-1893, is ...read more
Cardiovascular diseases biotech Braveheart Bio prices upsized IPO at $18, above the range
Braveheart Bio, a Phase 3-ready biotech developing oral small molecules for cardiovascular diseases, raised $383 million by offering 21.3 million shares at $18, above the $15 to $17 range. It had originally planned to offer 18.8 million shares. Fidelity had...read more
US IPO Week Ahead: August IPO market opens with biotechs, a bank, and SpaceX earnings
Updated Monday, 8/3. Six IPOs are currently scheduled for the week ahead, featuring five biotechs and a California bank. Mega-issuer SpaceX (SPCX) will also be in focus as it reports earnings for the first time as a public company ahead of a partial lock-up...read more